HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Waiting For FDA: Federal Courts Debate Stays Of 'Natural' Class Actions

This article was originally published in The Rose Sheet

Executive Summary

Mayer Brown attorney Dale Giali discusses the "natural" litigation landscape, where litigants increasingly are sparring over the appropriateness of stays in light of FDA's comment-gathering initiative launched in 2015.


Related Content

Industry Growth Makes Supplement Firms Bigger Litigation Targets
Adding Zarbee's, J&J Gains Natural Market Footprint, Claims Credibility
‘Hypoallergenic’ Class Actions Bubbling Up: The New ‘Natural’ Scourge?
Processing Removes 'Natural' Claim For UK Meal-Replacement Bar Ingredients
2017 In Review: Plaintiffs Find New Angles For Attacking Cosmetics' Authenticity
New ISO Natural/Organic Guidelines Draw Criticism From Standards Orgs
Plaintiffs May Be Sniffing Around 'Fragrance Free,' 'Hypoallergenic' Claims
FDA Seeks Comment On 'Natural' Food Labeling; Cosmetics Not Mentioned
Hain Celestial ‘Natural’ Case Could Set Precedent Favorable To Industry
Aveeno Faces Class Actions Over “Naturals” Claims





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts